Mepur Ravindranath, a former director of the laboratory of glycoimmunotherapy at the John Wayne Cancer Center in California, falsified the number of subjects in a double blind study of prostate cancer, according to an investigation by the Office of Research Integrity. Without admitting guilt, Ravindranath has agreed to have any work funded by the US Public Health Service supervised, among other stipulations.

Some of the data reported by Ravindranath represented samples taken from single patients over a period of time, but recorded as multiple individuals, potentially affecting the final analysis of the results, which were published in 2005 in the International Journal of Cancer. The paper, which studied the immune response in prostate cancer patients, has been cited 15 times since its publication, according to the Web of Science.

Ravindranath is settling without admitting to any of the charges, in the face of “undue financial hardship and stress,” which...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?